このページの翻訳は実験的なもので、現在開発中です。お待ちしております!
Charles River Laboratories International 将来の成長
Future 基準チェック /16
Charles River Laboratories International利益と収益がそれぞれ年間12.5%と5.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に14.2% 12.2%なると予測されています。
主要情報
12.5%
収益成長率
12.2%
EPS成長率
Life Sciences 収益成長 | 16.7% |
収益成長率 | 5.9% |
将来の株主資本利益率 | 14.2% |
アナリストカバレッジ | Good |
最終更新日 | 13 Jun 2024 |
今後の成長に関する最新情報
Recent updates
Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Charles River Laboratories International: A Great Business At A Decent Price
Feb 06Charles River acquires SAMDI Tech for $50M in cash
Jan 30Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?
Jan 24If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity
Jan 10Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital
Jan 05We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt
Dec 28Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Dec 14業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 4,874 | 596 | 615 | 942 | 12 |
12/31/2025 | 4,535 | 512 | 550 | 846 | 16 |
12/31/2024 | 4,221 | 410 | 438 | 726 | 16 |
3/30/2024 | 4,112 | 444 | 414 | 704 | N/A |
12/30/2023 | 4,129 | 475 | 365 | 684 | N/A |
9/30/2023 | 4,216 | 475 | 368 | 698 | N/A |
7/1/2023 | 4,178 | 484 | 289 | 625 | N/A |
4/1/2023 | 4,092 | 496 | 275 | 626 | N/A |
12/31/2022 | 3,976 | 486 | 295 | 620 | N/A |
9/24/2022 | 3,781 | 436 | 280 | 614 | N/A |
6/25/2022 | 3,688 | 443 | 338 | 656 | N/A |
3/26/2022 | 3,630 | 422 | 412 | 693 | N/A |
12/25/2021 | 3,540 | 391 | 532 | 761 | N/A |
9/25/2021 | 3,426 | 397 | 452 | 670 | N/A |
6/26/2021 | 3,273 | 396 | 484 | 672 | N/A |
3/27/2021 | 3,041 | 375 | 479 | 648 | N/A |
12/26/2020 | 2,924 | 364 | 380 | 547 | N/A |
9/26/2020 | 2,824 | 301 | 446 | 589 | N/A |
6/27/2020 | 2,749 | 271 | 416 | 567 | N/A |
3/28/2020 | 2,724 | 248 | 385 | 535 | N/A |
12/28/2019 | 2,621 | 252 | 340 | 481 | N/A |
9/28/2019 | 2,532 | 231 | 295 | 440 | N/A |
6/29/2019 | 2,449 | 219 | 269 | 402 | N/A |
3/30/2019 | 2,377 | 227 | 264 | 393 | N/A |
12/29/2018 | 2,266 | 225 | 297 | 437 | N/A |
9/29/2018 | 2,143 | 135 | 321 | 421 | N/A |
6/30/2018 | 2,022 | 128 | 264 | 363 | N/A |
3/31/2018 | 1,906 | 129 | 248 | 342 | N/A |
12/30/2017 | 1,858 | 123 | N/A | 316 | N/A |
9/30/2017 | 1,846 | 198 | N/A | 310 | N/A |
7/1/2017 | 1,807 | 183 | N/A | 323 | N/A |
4/1/2017 | 1,772 | 164 | N/A | 303 | N/A |
12/31/2016 | 1,681 | 154 | N/A | 315 | N/A |
9/24/2016 | 1,568 | 143 | N/A | 299 | N/A |
6/25/2016 | 1,492 | 143 | N/A | 315 | N/A |
3/26/2016 | 1,398 | 156 | N/A | 321 | N/A |
12/26/2015 | 1,363 | 150 | N/A | 305 | N/A |
9/26/2015 | 1,339 | 146 | N/A | 284 | N/A |
6/27/2015 | 1,317 | 140 | N/A | 263 | N/A |
3/28/2015 | 1,319 | 127 | N/A | 234 | N/A |
12/27/2014 | 1,298 | 128 | N/A | 251 | N/A |
9/27/2014 | 1,257 | 120 | N/A | 214 | N/A |
6/28/2014 | 1,222 | 119 | N/A | 214 | N/A |
3/29/2014 | 1,174 | 111 | N/A | 205 | N/A |
12/28/2013 | 1,166 | 104 | N/A | 207 | N/A |
9/28/2013 | 1,156 | 108 | N/A | 210 | N/A |
6/29/2013 | 1,143 | 99 | N/A | 203 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: CRLの予測収益成長率 (年間12.5% ) は 貯蓄率 ( 2.4% ) を上回っています。
収益対市場: CRLの収益 ( 12.5% ) US市場 ( 14.8% ) よりも低い成長が予測されています。
高成長収益: CRLの収益は増加すると予測されていますが、大幅には増加しません。
収益対市場: CRLの収益 ( 5.9% ) US市場 ( 8.7% ) よりも低い成長が予測されています。
高い収益成長: CRLの収益 ( 5.9% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: CRLの 自己資本利益率 は、3年後には低くなると予測されています ( 14.2 %)。